Nonsteroidal FXR Ligands: Current Status and Clinical Applications

Molecular basis of agonism and antagonism in the oestrogen receptor

Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355 · see citing works

Inflammatory Bowel Disease

Podolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,183 · see citing works

NAFLD: A multisystem disease

Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,082 · see citing works

Mechanisms of hepatic stellate cell activation

Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909 · see citing works

Identification of a nuclear receptor for bile acids

Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714 · see citing works

Bile Acids: Natural Ligands for an Orphan Nuclear Receptor

Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274 · see citing works

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial

Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · see citing works

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Huang, Y., Qi, Y., Peng, X., Wang, H., et al. (2012) · eLife · doi:10.7554/elife.00049 · Cited by 2,121 · see citing works

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · see citing works

A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis

Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00051-4 · Cited by 1,940 · see citing works

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865 · see citing works

Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis

Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · see citing works

The global NAFLD epidemic

Loomba, R. S., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,696 · see citing works

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678 · see citing works

Molecular Basis for Feedback Regulation of Bile Acid Synthesis by Nuclear Receptors

Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., & Mangelsdorf, D. J. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00050-2 · Cited by 1,487 · see citing works

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21025 · Cited by 1,398 · see citing works

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

Yki‐Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,260 · see citing works

Principles for modulation of the nuclear receptor superfamily

Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,228 · see citing works

Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis

Ripoll, C., Groszmann, R., Garcia–Tsao, G., Grace, N., Burroughs, A., Planas, R., Escorsell, A., Garcia–Pagan, J. C., Makuch, R., Patch, D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.024 · Cited by 1,183 · see citing works

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · see citing works

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067 · see citing works

Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease

Chávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970 · see citing works

Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice

Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 961 · see citing works

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · see citing works

Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor

Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M., & Edwards, P. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109326200 · Cited by 916 · see citing works

Farnesoid X receptor is essential for normal glucose homeostasis

Ma, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25604 · Cited by 883 · see citing works

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

Gadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut · doi:10.1136/gut.2010.212159 · Cited by 870 · see citing works

Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor

Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J., & Suchy, F. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011610200 · Cited by 804 · see citing works

6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity

Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743 · see citing works

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738 · see citing works

Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?

Lonardo, A., Nascimbeni, F., Mantovani, A., & Targher, G. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.021 · Cited by 737 · see citing works

Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesisPreprint

Holt, J. A., Luo, G., Billin, A. N., Bisi, J., McNeill, Y. Y., Kozarsky, K., Donahee, M. H., Wang, D. Y., Mansfield, T. A., Kliewer, S. A., et al. (2003) · Genes & Development · doi:10.1101/gad.1083503 · Cited by 698 · see citing works

Bile acid receptors as targets for drug development

Schaap, F. G., Trauner, M., & Jansen, P. L. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.151 · Cited by 696 · see citing works

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · see citing works

Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response

Wang, Y.-D., Chen, W.-D., Wang, M., Yu, D., Forman, B. M., & Huang, W. (2008) · Hepatology · doi:10.1002/hep.22519 · Cited by 639 · see citing works

Bile acids as carcinogens in human gastrointestinal cancers

Bernstein, H., Bernstein, C., Payne, C. M., Dvorakova, K., & Garewal, H. (2005) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2004.08.001 · Cited by 611 · see citing works

Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine Published, JLR Papers in Press, August 24, 2007.

Kim, I., Ahn, S.-H., Inagaki, T., Choi, M., Ito, S., Guo, G. L., Kliewer, S., & Gonzalez, F. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700330-jlr200 · Cited by 575 · see citing works

Intestine farnesoid X receptor agonist and the gut microbiota activate G‐protein bile acid receptor‐1 signaling to improve metabolism

Pathak, P., Xie, C., Nichols, R. G., Ferrell, J. M., Boehme, S., Krausz, K. W., Patterson, A. D., Gonzalez, F. J., & Chiang, J. Y. L. (2018) · Hepatology · doi:10.1002/hep.29857 · Cited by 567 · see citing works

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms10166 · Cited by 559 · see citing works

The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice

Cariou, B., van Harmelen, K., Durán-Sandoval, D., van Dijk, T. H., Grefhorst, A., Abdelkarim, M., Caron, S., Torpier, G., Fruchart, J., Gonzalez, F. J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510258200 · Cited by 546 · see citing works

Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR

Maloney, P., Parks, D. J., Haffner, C. D., Fivush, A. M., Chandra, G., Plunket, K. D., Creech, K. L., Moore, L. B., Wilson, J. G., Lewis, M. C., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002127 · Cited by 536 · see citing works

Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor

Yang, F., Huang, X., Yi, T., Yen, Y., Moore, D. D., & Huang, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1078 · Cited by 488 · see citing works

Bile acid nuclear receptor FXR and digestive system diseases

Ding, L., Yang, L., Wang, Z., & Huang, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.01.004 · Cited by 477 · see citing works

Hair dyes are mutagenic: identification of a variety of mutagenic ingredients.

Ames, B. N., Kammen, H. O., & Yamasaki, E. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.6.2423 · Cited by 475 · see citing works

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis

Fiorucci, S., Antonelli, E., Rizzo, G., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pellicciari, R., & Morelli, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.001 · Cited by 472 · see citing works

Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice

Kong, B., Wang, L., Chiang, J. Y. L., Zhang, Y., Klaassen, C. D., & Guo, G. L. (2012) · Hepatology · doi:10.1002/hep.25740 · Cited by 456 · see citing works

The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids

Puri, P., Daita, K., Joyce, A., Mirshahi, F., Santhekadur, P. K., Cazanave, S., Luketic, V. A., Siddiqui, M. S., Boyett, S., Min, H., et al. (2018) · Hepatology · doi:10.1002/hep.29359 · Cited by 426 · see citing works

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

Cipriani, S., Mencarelli, A., Palladino, G., & Fiorucci, S. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m001602 · Cited by 410 · see citing works

Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus

Kremer, A. E., Martens, J. J. W. W., Kulik, W., Ruëff, F., Kuiper, E. M. M., van Buuren, H. R., van Erpecum, K. J., Kondrackiene, J., Prieto, J., Rust, C., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.009 · Cited by 410 · see citing works

Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis

Liu, Y., Binz, J. G., Numerick, M. J., Dennis, S., Luo, G., Desai, B., MacKenzie, K. I., Mansfield, T. A., Kliewer, S. A., Goodwin, B. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18945 · Cited by 398 · see citing works

The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis

Lambert, G. C., Amar, M. J., Guo, G. L., Brewer, H. B., Gonzalez, F. J., & Sinal, C. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209525200 · Cited by 393 · see citing works

A Chemical, Genetic, and Structural Analysis of the Nuclear Bile Acid Receptor FXR

Downes, M., Verdecia, M. A., Roecker, A. J., Hughes, R. O., Hogenesch, J. B., Kast-Woelbern, H. R., Bowman, M. E., Ferrer, J.-L., Anisfeld, A. M., Edwards, P. A., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00104-7 · Cited by 392 · see citing works

FXR: a metabolic regulator and cell protector

Wang, Y.-D., Chen, W.-D., Moore, D. D., & Huang, W. (2008) · Cell Research · doi:10.1038/cr.2008.289 · Cited by 389 · see citing works

The TGR5 receptor mediates bile acid–induced itch and analgesia

Alemi, F., Kwon, E., Poole, D. P., Lieu, T., Lyo, V., Cattaruzza, F., Cevikbas, F., Steinhoff, M. S., Nassini, R., Materazzi, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64551 · Cited by 380 · see citing works

A Mouse Model of Hepatocellular Carcinoma

Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61177-7 · Cited by 359 · see citing works

FXR, a multipurpose nuclear receptor

Lee, F. Y., Lee, H., Hubbert, M. L., Edwards, P. A., & Zhang, Y. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.08.002 · Cited by 344 · see citing works

Pathology of non‐alcoholic fatty liver disease

Bédossa, P. (2017) · Liver International · doi:10.1111/liv.13301 · Cited by 324 · see citing works

Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTα-OSTβ in cholestasis in humans and rodents

Boyer, J. L., Trauner, M. A., Mennone, A., Soroka, C. J., Cai, S., Moustafa, T., Zollner, G., Lee, J., & Ballatori, N. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00539.2005 · Cited by 305 · see citing works

Pharmacotherapy for NASH: Current and emerging

Konerman, M. A., Jones, J. C., & Harrison, S. A. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.015 · Cited by 293 · see citing works

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis

Zhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290 · see citing works

Regulation of Carbohydrate Metabolism by the Farnesoid X Receptor

Stayrook, K. R., Bramlett, K. S., Savkur, R. S., FICORILLI, J. V., Cook, T. G., Christe, M. E., Michael, L. F., & Burris, T. P. (2004) · Endocrinology · doi:10.1210/en.2004-0965 · Cited by 288 · see citing works

Nuclear Receptors and Their Selective Pharmacologic Modulators

Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundåsen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 285 · see citing works

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology · doi:10.1002/hep.29569 · Cited by 281 · see citing works

Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis

Modica, S., Petruzzelli, M., Bellafante, E., Murzilli, S., Salvatore, L., Celli, N., Di Tullio, G., Palasciano, G., Moustafa, T., Halilbasic, E., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.028 · Cited by 275 · see citing works

Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease

Torres, D. M., Williams, C. D., & Harrison, S. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.011 · Cited by 269 · see citing works

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

Trauner, M. A., Gulamhusein, A. F., Hameed, B., Caldwell, S. H., Shiffman, M. L., Landis, C. S., Eksteen, B., Agarwal, K., Muir, A. J., Rushbrook, S., et al. (2019) · Hepatology · doi:10.1002/hep.30509 · Cited by 263 · see citing works

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

Verbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology · doi:10.1002/hep.26939 · Cited by 258 · see citing works

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

Tully, D. C., Rucker, P. V., CHIANELLI, D., Williams, J. A. S., Vidal, A., Alper, P. B., Mutnick, D., Bursulaya, B. D., Schmeits, J., Wu, X., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00907 · Cited by 241 · see citing works

Nuclear Bile Acid Receptor FXR Protects against Intestinal Tumorigenesis

Modica, S., Murzilli, S., Salvatore, L., Schmidt, D. R., & Moschetta, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1791 · Cited by 238 · see citing works

Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development

Maran, R. R. M., Thomas, A., Roth, M. E., Sheng, Z., Esterly, N., Pinson, D. M., Gao, X., Zhang, Y., Ganapathy, V., Gonzalez, F. J., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.145409 · Cited by 221 · see citing works

The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice

Lieu, T., Jayaweera, G., Zhao, P., Poole, D. P., Jensen, D. D., Grace, M. S., McIntyre, P., Bron, R., Wilson, Y. M., Krappitz, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.042 · Cited by 221 · see citing works

Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

French, D., Lin, B. C., Wang, M.-T., Adams, C. W., Shek, T., Hötzel, K., Bolon, B., Ferrando, R., Blackmore, C., Schroeder, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036713 · Cited by 216 · see citing works

FXR signaling in metabolic disease

Zhang, Y., & Edwards, P. A. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.11.015 · Cited by 209 · see citing works

The Tunable Functionality of α,β‐Unsaturated Carbonyl Compounds Enables Their Differential Application in Biological Systems

Amslinger, S. (2010) · ChemMedChem · doi:10.1002/cmdc.200900499 · Cited by 204 · see citing works

Protective Effects of 6-Ethyl Chenodeoxycholic Acid, a Farnesoid X Receptor Ligand, in Estrogen-Induced Cholestasis

Fiorucci, S., Clerici, C., Antonelli, E., Orlandi, S., Goodwin, B. J., Sadeghpour, B. M., Sabatino, G., Russo, G., Castellani, D., Willson, T. M., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079665 · Cited by 196 · see citing works

Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma

Miura, S., Mitsuhashi, N., Shimizu, H., Kimura, F., Yoshidome, H., Otsuka, M., Kato, A., Shida, T., Okamura, D., & Miyazaki, M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-56 · Cited by 193 · see citing works

Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.

Ho, H., Pok, S., Streit, S., Ruhe, J., Hart, S., Lim, K., Loo, H. L., Aung, M., Lim, S. G., & Ullrich, A. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.08.015 · Cited by 183 · see citing works

A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis

Fiorucci, S., Rizzo, G., Antonelli, E., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pruzanski, M., Morelli, A., & Pellicciari, R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084905 · Cited by 183 · see citing works

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19

Zhou, M., Wang, X., Phung, V., Lindhout, D. A., Mondal, K., Hsu, J.-Y., Yang, H., Humphrey, M., Ding, X., Arora, T., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0208 · Cited by 183 · see citing works

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction

Schwabl, P., Hambruch, E., Seeland, B. A., Hayden, H., Wagner, M., Garnys, L., Strobel, B., Schubert, T.-L., Riedl, F., Mitteregger, D., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.005 · Cited by 178 · see citing works

Cross-Talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor γ Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis

Fiorucci, S., Rizzo, G., Antonelli, E., Renga, B., Mencarelli, A., Riccardi, L., Morelli, A., Pruzanski, M., & Pellicciari, R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085597 · Cited by 177 · see citing works

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts

Fickert, P., Fuchsbichler, A., Moustafa, T., Wagner, M., Zollner, G., Halilbasic, E., Stöger, U., Arrese, M., Pizarro, M., Solís, N., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090114 · Cited by 169 · see citing works

The role of bile acids in carcinogenesis

Debruyne, P. R., Bruyneel, E. A., Li, X., Zimber, A., Gespach, C. P., & Mareel, M. M. K. (2001) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(01)00195-6 · Cited by 168 · see citing works

The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid

Walters, J. R. F., Johnston, I. M., Nolan, J. D., Vassie, C., Pruzanski, M., & Shapiro, D. A. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12999 · Cited by 167 · see citing works

Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)

Flatt, B., Martin, R., Wang, T., Mahaney, P. E., Murphy, B., Gu, X., Foster, P., Li, J., Pircher, P. C., Petrowski, M. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8014124 · Cited by 165 · see citing works

The Fibroblast Growth Factor Receptor-4 Arg388 Allele Is Associated with Prostate Cancer Initiation and Progression

Wang, J., Stockton, D. W., & Ittmann, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0408 · Cited by 156 · see citing works

Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice

Hartman, H. B., Gardell, S. J., Petucci, C. J., Wang, S., Krueger, J. A., & Evans, M. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800619-jlr200 · Cited by 155 · see citing works

The Farnesoid X Receptor Is Expressed in Breast Cancer and Regulates Apoptosis and Aromatase Expression

Swales, K. E., Korbonits, M., Carpenter, R., Walsh, D. T., Warner, T. D., & Bishop‐Bailey, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2399 · Cited by 154 · see citing works

Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease

Gadaleta, R. M., van Mil, S. W. C., Oldenburg, B., Siersema, P. D., Klomp, L. W. J., & van Erpecum, K. J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.04.006 · Cited by 147 · see citing works

Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice

de Boer, J. F., Schonewille, M., Boesjes, M., Wolters, H., Bloks, V. W., Bos, T., van Dijk, T. H., Jurdzinski, A., Boverhof, R., Wolters, J. C., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.037 · Cited by 142 · see citing works

Hepatic FXR: key regulator of whole-body energy metabolism

Teodoro, J. S., Rolo, A. P., & Palmeira, C. M. (2011) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2011.07.002 · Cited by 138 · see citing works

Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal

Schmitt, J., Kong, B., Stieger, B., Tschopp, O., Schultze, S. M., Rau, M., Weber, A., Müllhaupt, B., Guo, G. L., & Geier, A. (2014) · Liver International · doi:10.1111/liv.12456 · Cited by 136 · see citing works

The Bile Acid Nuclear Receptor FXR and the Bile Acid Binding Protein IBABP Are Differently Expressed in Colon Cancer

Gottardi, A. D., Touri, F., Maurer, C. A., Perez, A., Maurhofer, O., Ventre, G., Bentzen, C. L., Bentzen, E. J., & Dufour, J. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000034558.78747.98 · Cited by 134 · see citing works

A Comparison of ALPHAScreen, TR-FRET, and TRF as Assay Methods for FXR Nuclear Receptors

Glickman, J. F., Wu, X. Y., Mercuri, R., Illy, C., Bowen, B. R., He, Y., & Sills, M. A. (2002) · SLAS DISCOVERY · doi:10.1177/108705710200700102 · Cited by 128 · see citing works

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Bosch, J., & Iwakiri, Y. (2017) · Hepatology International · doi:10.1007/s12072-017-9827-9 · Cited by 124 · see citing works

Nuclear receptor coactivators: structural and functional biochemistry

Bulynko, Y. A., & O’Malley, B. W. (2011) · Biochemistry · doi:10.1021/bi101762x · Cited by 113 · see citing works

Role of FXR in Regulating Bile Acid Homeostasis and Relevance for Human Diseases

Rizzo, G., Renga, B., Mencarelli, A., Pellicciari, R., & Fiorucci, S. (2005) · Current Drug Targets - Immune Endocrine & Metabolic Disorders · doi:10.2174/1568008054863781 · Cited by 112 · see citing works

Nuclear bile acid signaling through the farnesoid X receptor

Mazuy, C., Helleboid, A., Staels, B., & Lefebvre, P. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1805-y · Cited by 111 · see citing works

Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis

Lax, S., Schauer, G., Prein, K., Kapitan, M., Silbert, D., Berghold, A., Berger, A., & Trauner, M. A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26293 · Cited by 100 · see citing works

Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (−/−) Mice

Hambruch, E., Miyazaki‐Anzai, S., Hahn, U. K., Matysik, S., Boettcher, A., Perović‐Ottstadt, S., Schlüter, T., Kinzel, O. D., Krol, H. D., Deuschle, U., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.196519 · Cited by 99 · see citing works

Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies

Lang, L., & Teng, Y. (2019) · Cells · doi:10.3390/cells8010031 · Cited by 99 · see citing works

Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation

Soisson, S. M., Parthasarathy, G., Adams, A. D., Sahoo, S. P., Sitlani, A., Sparrow, C. P., Cui, J., & Becker, J. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710981105 · Cited by 92 · see citing works

A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia

Evans, M. J., Mahaney, P. E., Borges-Marcucci, L., Lai, K., Wang, S., Krueger, J. A., Gardell, S. J., Huard, C., Martinez, R., Vlasuk, G. P., et al. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90585.2008 · Cited by 92 · see citing works

Farnesoid X Receptor Protects Hepatocytes From Injury by Repressing miR-199a-3p, Which Increases Levels of LKB1

Lee, C. G., Kim, Y., Kim, E. H., Meng, Z., Huang, W., Hwang, S. J., & Kim, S. G. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.007 · Cited by 89 · see citing works

Ileal FGF 15 contributes to fibrosis‐associated hepatocellular carcinoma development

Uriarte, I., Latasa, M. U., Carotti, S., Fernández‐Barrena, M. G., García‐Irigoyen, O., Elizalde, M., Urtasun, R., Gentilucci, U. V., Morini, S., Pulido, Á. D. M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29287 · Cited by 88 · see citing works

Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma

Xu, Y., Yang, X., Lü, X., Guo, S., Liu, Y., Iqbal, M., Ning, S., Yang, H., Suo, N., & Chen, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.050 · Cited by 88 · see citing works

FXR silencing in human colon cancer by DNA methylation and KRAS signaling

Bailey, A. M., Zhan, L., Maru, D. M., Shureiqi, I., Pickering, C. R., Kiriakova, G. M., Izzo, J. G., He, N., Wei, C., Baladandayuthapani, V., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00234.2013 · Cited by 85 · see citing works

FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model

Deuschle, U., Schüler, J. B., Schulz, A., Schlüter, T., Kinzel, O. D., Abel, U. R., & Kremoser, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043044 · Cited by 81 · see citing works

Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties

Richter, H. G., Benson, G. M., Bleicher, K., Blum, D., Chaput, E., Clemann, N., Feng, S., Gardès, C., Grether, U., HARTMAN, P. G., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.123 · Cited by 79 · see citing works

Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells

Li, J., Zhang, Y., Kuruba, R., Gao, X., Gandhi, C. R., Xie, W., & Li, S. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.068247 · Cited by 78 · see citing works

Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype

Murphy, T., Darby, S., Mathers, M. E., & Gnanapragasam, V. J. (2009) · The Journal of Pathology · doi:10.1002/path.2657 · Cited by 74 · see citing works

Novel and emerging therapies for cholestatic liver diseases

Goldstein, J., & Levy, C. (2018) · Liver International · doi:10.1111/liv.13880 · Cited by 74 · see citing works

Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities

Gege, C., Kinzel, O., Steeneck, C., Schulz, A., & Kremoser, C. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666141112094430 · Cited by 69 · see citing works

Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer

Jiang, Y., Iakova, P. A., Jin, J., Sullivan, E. M., Sharin, V. G., Hong, I., Anakk, S., Mayor, A., Darlington, G., Finegold, M. J., et al. (2012) · Hepatology · doi:10.1002/hep.26146 · Cited by 66 · see citing works

Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand

Li, J., Kuruba, R., Wilson, A., Gao, X., Zhang, Y., & Li, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013955 · Cited by 66 · see citing works

In Vivo Imaging of Farnesoid X Receptor Activity Reveals the Ileum as the Primary Bile Acid Signaling Tissue

Houten, S. M., Volle, D. H., Cummins, C. L., Mangelsdorf, D. J., & Auwerx, J. H. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0113 · Cited by 65 · see citing works

Ligand binding and heterodimerization with retinoid X receptor α (RXRα) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding

Wang, N., Zou, Q., Xu, J., Zhang, J., & Liu, J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004652 · Cited by 65 · see citing works

The Farnesoid X Receptor: Good for BAD

Keely, S. J., & Walters, J. R. F. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.08.004 · Cited by 64 · see citing works

Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

Genin, M. J., Bueno, A. B., Agejas, F. J., Manninen, P. R., Bocchinfuso, W. P., Montrose‐Rafizadeh, C., Cannady, E. A., Jones, T. M., Stille, J. R., Raddad, E., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01161 · Cited by 63 · see citing works

Steatosis and NASH in type 2 diabetes

Hu, M., Phan, F., Bourron, O., Ferré, P., & Foufelle, F. (2017) · Biochimie · doi:10.1016/j.biochi.2017.10.019 · Cited by 63 · see citing works

Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic

FILOZOF, C. M., Chow, S., Dimick‐Santos, L., Chen, Y., Williams, R. N., Goldstein, B. J., & Sanyal, A. J. (2017) · Hepatology Communications · doi:10.1002/hep4.1079 · Cited by 61 · see citing works

Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes

Richter, H. G., Benson, G. M., Blum, D., Chaput, E., Feng, S., Gardès, C., Grether, U., HARTMAN, P. G., Kuhn, B., Martin, R. E., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.039 · Cited by 60 · see citing works

Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease

Attinkara, R., Mwinyi, J., Truninger, K., Reguła, J., Gaj, P., Rogler, G., Kullak-Ublick, G. A., Eloranta, J. J., & The Swiss IBD Cohort Study Group (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-461 · Cited by 54 · see citing works

Targeting FXR in cholestasis: hype or hope

Fiorucci, S., Distrutti, E., Ricci, P., Giuliano, V., Donini, A., & Baldelli, F. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.956087 · Cited by 53 · see citing works

Improvement of Physiochemical Properties of the Tetrahydroazepinoindole Series of Farnesoid X Receptor (FXR) Agonists: Beneficial Modulation of Lipids in Primates

Lundquist, J. T. I., Harnish, D. C., Kim, C. Y., Mehlmann, J. F., Unwalla, R. J., Phipps, K. M., Crawley, M. L., Commons, T., Green, D. M., Xu, W., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901650u · Cited by 53 · see citing works

Farnesoid X receptor signaling activates the hepatic X‐box binding protein 1 pathway in vitro and in mice

Liu, X., Guo, G. L., Kong, B., Hilburn, D. B., Hubchak, S. C., Park, S., LeCuyer, B. E., Hsieh, A., Wang, L., Fang, D., et al. (2018) · Hepatology · doi:10.1002/hep.29815 · Cited by 46 · see citing works

Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr −/− mice versus hamsters

Gardès, C., Chaput, E., Staempfli, A. A., Blum, D., Richter, H. G., & Benson, G. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m033423 · Cited by 42 · see citing works

Reciprocal regulation of farnesoid X receptor α activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes

Radreau, P., Porcherot, M., Ramière, C., Mouzannar, K., Lotteau, V., & André, P. (2016) · The FASEB Journal · doi:10.1096/fj.201500134 · Cited by 42 · see citing works

Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction

Liu, X., Xue, R., Ji, L., Zhang, X., Wu, J. H., Gu, J., Zhou, M., & Chen, S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.05.072 · Cited by 42 · see citing works

Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4−/− Mice

Cariello, M., Peres, C., Zerlotin, R., Porru, E., Sabbà, C., Roda, A., & Moschetta, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-11549-7 · Cited by 39 · see citing works

New therapeutical indications of ursodeoxycholic acid.

Copaci, I., Micu, L., Iliescu, L. E., & Voiculescu, M. (2005) · PubMed · Cited by 38 · see citing works

Bile Acid Receptor Agonist GW4064 Regulates PPARγ Coactivator-1α Expression Through Estrogen Receptor-Related Receptor α

Dwivedi, S. K. D., Singh, N., Kumari, R., Mishra, J. S., Tripathi, S., Banerjee, P., Shah, P., Kukshal, V., Tyagi, A. M., Gaikwad, A. N., et al. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0512 · Cited by 36 · see citing works

Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: understanding and improving key determinants of pharmacological properties

Kinzel, O., Steeneck, C., Schlüter, T., Schulz, A., Gege, C., Hahn, U., Hambruch, E., Hornberger, M., Spalwisz, A., Frick, K., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.05.070 · Cited by 35 · see citing works

Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.

Hannah, W. N., Torres, D. M., & Harrison, S. A. (2016) · PubMed Central · Cited by 32 · see citing works

The Molecular Mechanism of Cholestatic Pruritus

Elferink, R. P. J. O., Kremer, A. E., Martens, J. J. W. W., & Beuers, U. H. (2011) · Digestive Diseases · doi:10.1159/000324131 · Cited by 32 · see citing works

Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators

Kremoser, C., Albers, M., Burris, T. P., Deuschle, U., & Koegl, M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.025 · Cited by 24 · see citing works

Steroidal or non-steroidal FXR agonists – Is that the question?

Verbeke, L., Nevens, F., & Laleman, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.013 · Cited by 24 · see citing works

Fxr Agonism by Gs-9674 Decreases Steatosis and Fibrosis in a Murine Model of Nash

Liles, J., Karnik, S. K., Hambruch, E., Kremoser, C., Birkel, M., Watkins, W. J., Tumas, D. B., Breckenridge, D. G., & French, D. (2016) · Journal of Hepatology · doi:10.1016/s0168-8278(16)01682-2 · Cited by 21 · see citing works

PC.01.8 THE AESOP TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS

LaRusso, N. F., Bowlus, C. L., Levy, C., Vuppalanchi, R., Floreani, A., Andreoné, P., Srestha, R., Trotter, J. F., Goldberg, D. S., Rushbrook, S., et al. (2018) · Digestive and Liver Disease · doi:10.1016/s1590-8658(18)30266-4 · Cited by 16 · see citing works

A198 PHARMACODYNAMIC EFFECTS OF THE ORAL, NON-STEROIDAL FARNESOID X RECEPTOR AGONIST GS-9674 IN HEALTHY VOLUNTEERS

Myers, R., Djedjos, C. S., Kirby, B., Bilin, A., Khan, M., Gosink, J. J., Song, Q., & Srihari, R. (2018) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwy008.199 · Cited by 14 · see citing works

The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells

Joly, S., Porcherot, M., Radreau, P., Vonderscher, J., André, P., Meldrum, E., Arold, G., de Rooij, J. V. D. W., Staner, C., Laveille, C., et al. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)31853-6 · Cited by 11 · see citing works

Targeting Farnesoid X Receptor in Hepatic and Biliary Inflammatory Diseases

Chignard, N., & Poupon, R. Y. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.027 · Cited by 11 · see citing works

964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC)

Marschall, H.-U., Luketic, V., Lovgren-Sandblom, A., Benthin, L., Kowdley, K., Hirschfield, G., Mason, A., Lindor, K., Gordon, S., Vincent, C., et al. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60976-3 · Cited by 9 · see citing works

99 NOVEL FXR AGONISTS WITH POTENT LIPID LOWERING, INSULIN SENSITISING, ANTI-INFLAMMATORY AND ANTI-FIBROTISATION EFFECTS IN MOUSE MODELS OF METABOLIC SYNDROME AND NASH

Kremoser, C., Hambruch, E., Deuschle, U., Kinzel, O. D., Burnet, M. W. M., & Yoneyama, H. (2011) · Journal of Hepatology · doi:10.1016/s0168-8278(11)60101-3 · Cited by 3 · see citing works

First-in-Human study of LMB763, a novel, orally-available farnesoid X receptor agonist that demonstrates modulation of the pharmacodynamic markers FGF19 and C4 in healthy subjects

Huttner, K. M., Desai, S. D., DeCristofaro, M. F., Laffitte, B. A., Lin, T., Chen, J., Klickstein, L. B., & Badman, M. K. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)31214-x · Cited by 3 · see citing works

The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC.

Trauner, M. A., Gulamhusein, A. F., Hameed, B., Caldwell, S. H., Shiffman, M. L., Landis, C. S., Eksteen, B., Agarwal, K., Muir, A. J., Rushbrook, S., et al. (2019) · Hepatology · Cited by 3 · see citing works

Su1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH

Lawitz, E., Herring, R., Younes, Z. H., Gane, E. J., Ruane, P. J., Aguilar, R., Jia, C., Xu, R., Mccolgan, B., Natha, M., et al. (2018) · Gastroenterology · doi:10.1016/s0016-5085(18)33863-0 · Cited by 3 · see citing works

Gut-liver axis: Pathophysiological concepts and clinical implications

Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843 · see citing works

Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy

Chiang, J. Y. L., & Ferrell, J. M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2019 · Cited by 580 · see citing works

The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer

Sun, L., Cai, J., & Gonzalez, F. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00404-2 · Cited by 443 · see citing works

Discovery of farnesoid X receptor and its role in bile acid metabolism

Chiang, J. Y. L., & Ferrell, J. M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111618 · Cited by 298 · see citing works

Bile acids and their receptors in metabolic disorders

Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 262 · see citing works

Farnesoid X receptor (FXR): Structures and ligands

Jiang, L., Zhang, H., Xiao, D., Wei, H., & Chen, Y. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.029 · Cited by 236 · see citing works

Novel therapeutic targets for cholestatic and fatty liver disease

Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204 · see citing works

FXR in liver physiology: Multiple faces to regulate liver metabolism

Panzitt, K., & Wagner, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166133 · Cited by 160 · see citing works

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease

Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 126 · see citing works

FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid

Wang, K., Zhang, Y., Wang, G., Hao, H., & Wang, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21991 · Cited by 121 · see citing works

Mechanisms of pruritus in cholestasis: understanding and treating the itch

Beuers, U. H., Wolters, F., & Elferink, R. P. J. O. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00687-7 · Cited by 112 · see citing works

Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis

Simbrunner, B., Trauner, M. A., & Reiberger, T. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16602 · Cited by 107 · see citing works

Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)

Fiorucci, S., Biagioli, M., Sepe, V., Zampella, A., & Distrutti, E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1763302 · Cited by 99 · see citing works

Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH

Kang, G. G., Trevaskis, N. L., Murphy, A. J., & Febbraio, M. A. (2023) · iScience · doi:10.1016/j.isci.2022.105905 · Cited by 94 · see citing works

FXR: structures, biology, and drug development for NASH and fibrosis diseases

Tian, S., Chen, S., Pan, C., & Li, Y. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00849-4 · Cited by 93 · see citing works

Recent advances on FXR-targeting therapeutics

Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 86 · see citing works

The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids

Ducastel, S., Touche, V., Trabelsi, M.-S., Boulinguiez, A., Butruille, L., Nawrot, M., Peschard, S., Chávez-Talavera, O., Dorchies, E., Vallez, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56743-x · Cited by 84 · see citing works

Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities

Vesterhus, M. N., & Karlsen, T. H. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01681-z · Cited by 80 · see citing works

Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Radun, R., & Trauner, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731707 · Cited by 81 · see citing works

The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity

Anderson, K. M., & Gayer, C. P. (2021) · Cells · doi:10.3390/cells10113206 · Cited by 81 · see citing works

Immunomodulatory functions of FXR.

Fiorucci, S., Zampella, A., Ricci, P., Distrutti, E., & Biagioli, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111650 · Cited by 67 · see citing works

Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders

Fiorucci, S., Baldoni, M., Ricci, P., Zampella, A., Distrutti, E., & Biagioli, M. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.04.008 · Cited by 69 · see citing works

Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling

Ciaula, A. D., Bonfrate, L., Baj, J., Khalil, M., Garruti, G., Stellaard, F., Wang, H. H., Wang, D. Q. ‐., & Portincasa, P. (2022) · Nutrients · doi:10.3390/nu14234950 · Cited by 73 · see citing works

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics

Park, J. W., Kim, J. H., Kim, S. E., Jung, J. H., Jang, M. K., Park, S. H., Lee, M. S., Kim, H. S., Suk, K. T., & Kim, D. J. (2022) · Biomedicines · doi:10.3390/biomedicines10061288 · Cited by 58 · see citing works

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

An, P., Wei, G., Huang, P., Li, W., Qi, X., Lin, Y., Vaid, K. A., Wang, J., Zhang, S., Li, Y., et al. (2020) · Liver International · doi:10.1111/liv.14490 · Cited by 57 · see citing works

The Role of Gut Microbiota and Its Produced Metabolites in Obesity, Dyslipidemia, Adipocyte Dysfunction, and Its Interventions

Zwartjes, M. S. Z., Gerdes, V. E. A., & Nieuwdorp, M. (2021) · Metabolites · doi:10.3390/metabo11080531 · Cited by 50 · see citing works

Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases†

Nevens, F., Trauner, M. A., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 51 · see citing works

Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis

Carino, A., Biagioli, M., Marchianò, S., Fiorucci, C., Bordoni, M., Roselli, R., Giorgio, C. D., Baldoni, M., Ricci, P., Monti, M. C., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158733 · Cited by 48 · see citing works

Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update

Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 43 · see citing works

Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders

Fiorucci, S., Urbani, G., Distrutti, E., & Biagioli, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091424 · Cited by 41 · see citing works

Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease.

Wang, S.-D., Yin, J., Liu, Z., Liu, X., Tian, G., Xin, X., Qin, Y., & Feng, X.-J. (2024) · Life Science · doi:10.1016/j.lfs.2024.123211 · Cited by 43 · see citing works

Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease

Biagioli, M., & Fiorucci, S. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.003 · Cited by 31 · see citing works

Therapeutic modulation methods of gut microbiota and gut-liver axis

Coşkun, A. B., & Celep, G. S. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1902263 · Cited by 32 · see citing works

Targeting bile acid signaling for the treatment of liver diseases: From bench to bed

Duan, S., Li, X., Fan, G., & Liu, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113154 · Cited by 33 · see citing works

The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease

Fiorucci, S., Biagioli, M., Baldoni, M., Ricci, P., Sepe, V., Zampella, A., & Distrutti, E. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1916465 · Cited by 31 · see citing works

Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review

Lonardo, A. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.07 · Cited by 32 · see citing works

Role of FXR in Renal Physiology and Kidney Diseases

Guo, Y., Xie, G., & Zhang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032408 · Cited by 32 · see citing works

Bile acids and their receptors in hepatic immunity

Fiorucci, S., Marchianò, S., Distrutti, E., & Biagioli, M. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.005 · Cited by 28 · see citing works

Advances in the pharmacological management of bacterial peritonitis

Pörner, D., von Vietinghoff, S., Nattermann, J., Strassburg, C. P., & Lutz, P. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1915288 · Cited by 26 · see citing works

Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis

Cao, S., Yang, X., Zhang, Z., Wu, J., Chi, B., Chen, H., Yu, J., Feng, S., Xu, Y., Li, J., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114089 · Cited by 26 · see citing works

Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts

Fujimori, K., Iguchi, Y., Yamashita, Y., Gohda, K., & Teno, N. (2019) · Molecules · doi:10.3390/molecules24224155 · Cited by 25 · see citing works

Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders

Fiorucci, S., Sepe, V., Biagioli, M., Fiorillo, B., Rapacciuolo, P., Distrutti, E., & Zampella, A. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115776 · Cited by 23 · see citing works

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Tong, Q., Gao, X., Lei, L., Feng, J., Zhang, W., Hu, Y., Shen, Z., Liu, Z., Huan, Y., Wu, S., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115307 · Cited by 20 · see citing works

Chemogenomics for drug discovery: clinical molecules from open access chemical probes

Quinlan, R. B. A., & Brennan, P. E. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00016k · Cited by 18 · see citing works

Farnesoid X receptor: a potential therapeutic target in multiple organs.

Zhang, C., Wang, Z., Feng, Q., Chen, W.-D., & Wang, Y.-D. (2021) · Histology and Histopathology · doi:10.14670/hh-18-301 · Cited by 16 · see citing works

The gut-liver axis in hepatobiliary diseases

Ichikawa, M., Okada, H., Nakamoto, N., Taniki, N., Chu, P., & Kanai∥, T. (2024) · Inflammation and Regeneration · doi:10.1186/s41232-023-00315-0 · Cited by 18 · see citing works

Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis.

Chen, C., Zhang, B., Tu, J., Peng, Y., Zhou, Y., Yang, X.-P., Yu, Q.-M., & Tan, X. (2023) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2023.115992 · Cited by 16 · see citing works

The role of intestinal flora in metabolic dysfunction-associated steatotic liver disease and treatment strategies

Wang, L. J., Sun, J., Chen, S., Sun, Y., Zheng, Y., & Feng, J. C. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1490929 · Cited by 18 · see citing works

Enhancement of Farnesoid X Receptor Inhibits Migration, Adhesion and Angiogenesis through Proteasome Degradation and VEGF Reduction in Bladder Cancers

Lai, C.-R., Wang, H.-H., Chang, H., Tsai, Y., Tsai, W., Lee, C.-R., Changchien, C., Cheng, Y., Wu, S., & Chen, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095259 · Cited by 15 · see citing works

Discovery of (E)-3-(3-((2-Cyano-4′-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis

Shim, S., Krishnaiah, M., Sankham, M. R., Kim, I., Lee, Y., Shin, I., Oh, A., Lee, H. J., Vu, T. N. L., Park, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00641 · Cited by 14 · see citing works

Review article: insights into the bile acid‐gut microbiota axis in intestinal failure‐associated liver disease—redefining the treatment approach

Wang, Y., Zheng, L., Zhou, Z., Yao, D., Huang, Y., Liu, B., Duan, Y., & Li, Y. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16676 · Cited by 12 · see citing works

Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD

Tong, Q., Gao, X., Lei, L., Zhang, W., Feng, J., Wang, X., Shen, Z., Liu, Z., Yi, H., Wu, S., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114903 · Cited by 11 · see citing works

A new serotonin 2A receptor antagonist with potential benefits in Non-Alcoholic Fatty Liver Disease

Sessa, L., Concilio, S., Fominaya, J. M., Eletto, D., Piotto, S., & Busquets, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121315 · Cited by 11 · see citing works

Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease

Wang, J., Yang, N., & Xu, Y. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500137 · Cited by 10 · see citing works

Itching for Answers: A Comprehensive Review of Cholestatic Pruritus Treatments

Gabrielli, F., Crepaldi, E., Cavicchioli, A., Rivi, M., Costanzo, A. A. C., Cursaro, C., & Andreoné, P. (2024) · Biomolecules · doi:10.3390/biom14101227 · Cited by 10 · see citing works

The role of bile salts in itch receptor activation

Wolters, F., Tolenaars, D., van Weeghel, M., de Waart, D. R., van de Graaf, S. F. J., Paulusma, C. C., Verhoeven, A. J., Beuers, U. H., & Elferink, R. P. J. O. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167972 · Cited by 7 · see citing works

miR-199a-5p inhibits the expression of ABCB11 in obstructive cholestasis

Balasubramaniyan, N., Devereaux, M. W., Orlicky, D. J., Sokol, R. J., & Suchy, F. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101400 · Cited by 6 · see citing works

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists

Zhao, S., Peng, W., Li, X., Wang, L., Yin, W., Wang, Y., Hou, R., & Chen, W. (2021) · RSC Advances · doi:10.1039/d0ra09320c · Cited by 6 · see citing works

Lactiplantibacillus plantarum Lp20 Alleviates High Fat Diet-Induced Obesity in Mice via Its Bile Salt Hydrolase Activity

Bai, X., Lu, F., Jing, Y., Wang, H., Qian, H., Zhang, M., Zhai, Z., & Hao, Y. (2025) · Nutrients · doi:10.3390/nu17223555 · Cited by 5 · see citing works

Direct degradation and stabilization of proteins: New horizons in treatment of nonalcoholic steatohepatitis

Wang, Y., Zheng, J., Long, Y., Wu, W., & Zhu, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115989 · Cited by 5 · see citing works

Hepatic bile acid accretion correlates with cholestatic liver injury and therapeutic response in Cyp2c70 knockout mice with a humanized bile acid composition

Klindt, C., Truong, J. K., Bennett, A. L., Pachura, K. J., Herebian, D. A., Mayatepek, E., Luedde, T., Ebert, M. P. A., Karpen, S. J., & Dawson, P. A. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00129.2024 · Cited by 5 · see citing works

An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance

Sahu, R., Mishra, R., & Majee, C. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1797485 · Cited by 5 · see citing works

Structure Modification of FXR Antagonistic Chalcones and Their Inhibitory Effects on NSCLC Cell Proliferation and Metastasis

Niu, S., Zhang, G., Wang, N., Lv, G., Liu, J., Wang, H., & Fang, W. (2022) · ChemMedChem · doi:10.1002/cmdc.202100778 · Cited by 4 · see citing works

Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist

He, H., & Wu, J. J. (2023) · Drugs in R&D · doi:10.1007/s40268-023-00444-4 · Cited by 4 · see citing works

FXR expression in rats of hilar cholangiocarcinoma

Zhang, M., Luo, M., & Wang, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-12850-w · Cited by 3 · see citing works

Targeting the ileal bile salt transporter in the treatment of non-alcoholic fatty liver disease

Jansen, P. L. M. (2021) · Hepatology International · doi:10.1007/s12072-021-10134-5 · Cited by 3 · see citing works

The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets

Sahu, P., & Satapathy, T. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11050-6 · Cited by 2 · see citing works

Early Development and Kilogram Scale-Up of a Non-steroidal FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)

Cizio, G. T., Dao, K., Doerffler, E. M., Griggs, N. D., Ischay, M. A., Kang, B. S., Logan, M. M., MacLeod, P. D., Weinstein, A. B., & Yu, L. H. L. (2021) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00193 · Cited by 2 · see citing works

Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders

Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1 · see citing works

Decoding structural and dynamic determinants of Tropifexor-FXR binding: A comprehensive computational analysis

Sinha, S., & Kumar, R. (2026) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2026.109352 · Cited by 1 · see citing works

Design, synthesis, and biological evaluation of novel FXR agonists based on auraptene

Qiu, Q., Wang, Y., Gu, G., Fan, Y., Zhang, S., Zhao, Y., & Ling, B. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105198 · Cited by 1 · see citing works

Effective medical treatments for PSC needed ASAP - is AESOP the answer?

Trauner, M. A. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.009 · Cited by 1 · see citing works

Lactiplantibacillus plantarum Lp20 Alleviates High Fat Diet-Induced Obesity in Mice via Its Bile Salt Hydrolase ActivityPreprint

Lu, F., Wang, H., Qian, H., Zhai, Z., & Hao, Y. (2024) · Preprints.org · doi:10.20944/preprints202406.0235.v1

Hepatic Expression of Fibroblast Growth Factor 19 Significantly Correlates With Serum Bile Acids in Neonatal Cholestasis

Fouad, O. A., Zaghlol, D. F., Sweed, D., Saber, M. A., & Sıra, M. M. (2025) · Pediatric and Developmental Pathology · doi:10.1177/10935266251322941

Roles of Pharmacophores in Drug Discovery

Thai, K., Duong, C. Q., Tran, V.-T., & Nguyen, P. T. V. (2025) · Springer handbooks · doi:10.1007/978-3-031-81728-1_21

Influence of bile acids metabolism on hepatic immunity in mice

Guinot, V. (2022) · doi:10.70675/b69bb11eza30fz4874z9af2za6e31b2d5ad8

Rôle du récepteur Farnesoid X dans le contrôle central de l'homéostasie énergétique

Deckmyn, B. (2022) · doi:10.70675/db76bb16z01f4z4f26zaf99za1003045be0c

Etude de la zonation des voies métaboliques du glucose en fonction du statut nutritionnel : implication du récepteur nucléaire Farnesoid X Receptor (FXR)

Loubota, A. C. N. (2024) · doi:10.70675/406936f5zb422z453ez84d1z38c3f35b82e9

Development of a Scalable Synthesis for the Spirocyclic Benzoxepane–Pyridine Core of FXR Agonist HEC96719

Zhang, J., Wu, J., Pan, S., Chen, H., Wang, Z., Lu, X., Yang, X., & Zhang, Y. J. (2026) · Organic Process Research & Development · doi:10.1021/acs.oprd.6c00078

First-in-Human Dose Selection, Pharmacokinetics Prediction, and Clinical Validation of SYHA1805, a Novel FXR Agonist, Using Allometric Scaling and PBPK Modeling

Zhang, L., Zhang, M., Zhou, E., Zhang, X., Qi, H., Yao, X., & Liu, D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070862

BindingDB Entry 50017303: Discovery of (

BindingDB (2023) · UC San Diego · doi:10.7270/q2k35zr8

BindingDB Entry 50021593: Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis.

BindingDB (2025) · UC San Diego · doi:10.7270/q2891bjw

BindingDB Entry 50017588: Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis.

BindingDB (2023) · UC San Diego · doi:10.7270/q2tt4w12

BindingDB Entry 50020153: Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease.

BindingDB (2024) · UC San Diego · doi:10.7270/q2vh5t8z

BindingDB Entry 50020729: Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD.

BindingDB (2024) · UC San Diego · doi:10.7270/q2pr81fp

BindingDB Entry 50007641: The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.

BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg

FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid

Wang, K., Zhang, Y., Wang, G., Hao, H., & Wang, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21991 · Cited by 121 · see citing works

Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders

Fiorucci, S., Urbani, G., Distrutti, E., & Biagioli, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091424 · Cited by 41 · see citing works

Obeticholic Acid—A Pharmacological and Clinical Review

Keshvani, C., Kopel, J. J., & Goyal, H. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010017 · Cited by 10 · see citing works

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis (NASH)

CHIANELLI, D., Rucker, P. V., Tully, D. C., Nelson, J. T., Liu, X., Bursulaya, B. D., Hernandez, E. D., Chu, A. C., Schmeits, J., Hill, R., et al. (2020) · The Novartis Repository (Novartis)

Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio

Tang, X., Ning, M., Ye, Y., Gu, Y., Yan, H., Leng, Y., & Shen, J. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116280 · Cited by 8 · see citing works